Pharmaceuticals News and Research

RSS

Regulus reports net loss of $7.2 million for fourth quarter 2015

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported financial results for the fourth quarter and full-year ended December 31, 2015 and provided a summary of recent corporate highlights.

23 Feb 2016

Patient enrollment completed in vepoloxamer Phase 3 study for treatment of sickle cell disease

Mast Therapeutics, Inc., a biopharmaceutical company developing novel, clinical-stage therapies for sickle cell disease and heart failure today announced that it has completed patient enrollment in its Phase 3 clinical study of vepoloxamer for the treatment of patients with sickle cell disease experiencing vaso-occlusive crisis, known as the EPIC study.

22 Feb 2016

Dr. Elliot J. Androphy receives IGNITE grant to develop drug candidate for spinal muscular atrophy

Dr. Elliot J. Androphy, the Kampen-Norins Professor and chair of the Department of Dermatology at the Indiana University School of Medicine, has been awarded an IGNITE, or Innovation Grants to Nurture Initial Translational Efforts, grant by the National Institutes of Health.

22 Feb 2016

Antibody can give more precise information about Alzheimer's disease than regular radioactive tracers

For the first time, researchers have succeeded in passing an antibody through the blood-brain barrier to act as a tracer for PET imaging of the brain. This resulted in more precise information being obtained than with regular radioactive tracers. The study provides hope for more effective diagnosis of early onset Alzheimer's disease and improvements in monitoring the effects of medication.

22 Feb 2016

Researchers identify new group of powerful Ebola-fighting antibodies

A research team that included scientists from The Scripps Research Institute has identified a new group of powerful antibodies to fight Ebola virus.

22 Feb 2016

New visiongain report on Zika virus

What can be expected as the Zika outbreak progresses? Which areas are going to be the most affected? This visiongain report discusses the future direction of the Zika virus outbreak and the implications of its spread. It also discussed the infectious disease diagnostics market and the global human vaccines market, both of which are forecast to 2026.

22 Feb 2016

Novartis receives FDA Breakthrough Therapy designation for PKC412 (midostaurin)

Novartis announced today that the United States Food and Drug Administration has granted Breakthrough Therapy designation to PKC412 (midostaurin). PKC412 (midostaurin) is an investigational treatment for adults with newly-diagnosed AML who are FLT3 mutation-positive, as detected by an FDA-approved test, and who are eligible to receive standard induction and consolidation chemotherapy.

19 Feb 2016

Duke engineers develop technique to make artificial arteries that produce biochemical signals

Duke engineers have developed a technique to make artificial arteries that naturally produce biochemical signals vital to their functions. The technique is also ten times faster than current methods for tissue engineering of blood vessels.

19 Feb 2016

New approach could open door to more personalized medications for diabetes patients

New research from the University of Copenhagen points to an entirely new approach for designing insulin-based pharmaceuticals. The approach could open the door for more personalized medications with fewer side effects for Type 1 Diabetes patients.

19 Feb 2016

Parvus' novel therapeutic approach employing nanomedicines published in Nature

Parvus Therapeutics today announced the publication in Nature of a seminal paper describing the discovery and applications of a novel therapeutic approach employing nanomedicines, referred to as "Navacims"TM, to reprogram white blood cells to become regulatory cells capable of blunting autoimmune responses and restoring the equilibrium of the immune system.

19 Feb 2016

African Americans and Hispanics at higher risk of developing heart failure

More than 915,000 Americans will be diagnosed with heart failure this year, according to the recently published American Heart Association 2016 Statistical Update.

18 Feb 2016

BiondVax gains additional support from NATI for ongoing development of Universal Flu Vaccine

BiondVax Pharmaceuticals Ltd. announced today that the National Authority for Technological Innovation, formerly known as the Office of the Chief Scientist, agreed to fund up to 40% of a NIS 3.6 million (US$920,000) project towards ongoing development of the Company's Universal Flu Vaccine.

18 Feb 2016

New treatment protects mice from MERS infection

In a new study, University of Maryland School of Medicine researchers have had promising results with a new treatment for Middle East Respiratory Syndrome (MERS). The study, published today in the journal Science Translational Medicine, found a new treatment that protected mice from MERS infection.

18 Feb 2016

Corvidia Therapeutics secures $26 million in Series A financing

Corvidia Therapeutics, a biotechnology company focused on the development of precision cardiovascular therapies, announced today that it has raised $26 million in a Series A financing, co-led by seed-investor Sofinnova Partners, and Apple Tree Partners.

18 Feb 2016

Enzyme screening kits and samples global distribution agreement signed between Strem and Novozymes

Strem Chemicals, Inc., a manufacturer of specialty chemicals for research and development, and Novozymes, the world’s largest producer of industrial enzymes, today announced the signing of a distribution agreement.

17 Feb 2016

AMRI's net revenues increase $126.4M to 46% in fourth quarter 2015

AMRI today reported financial and operating results for the fourth quarter and full year ended December 31, 2015 and provided an outlook for 2016.

17 Feb 2016

Green tea compound has high potential as treatment for rheumatoid arthritis

Researchers at Washington State University in Spokane have identified a potential new approach to combating the joint pain, inflammation and tissue damage caused by rheumatoid arthritis.

17 Feb 2016

WRAIR begins Phase 1 clinical trial to evaluate MERS vaccine candidate

The Walter Reed Army Institute of Research began vaccinations today in a Phase 1 clinical trial to evaluate the safety and immune response of a vaccine candidate to prevent Middle East Respiratory Syndrome (MERS).

17 Feb 2016

Aytu BioScience announces business strategy update and Q2 financial results

Aytu BioScience, Inc., a specialty healthcare company focused on developing treatments for urological and related conditions, provided today an overview of its business and growth strategy, as well as its financial results for the quarter ended December 31, 2015.

17 Feb 2016

Apogenix awarded €3 million grant to develop immuno-oncology candidate APG101 as personalized therapy

Apogenix, a biopharmaceutical company developing next generation immuno-oncology therapeutics, announced today that it has received funding approval in the amount of €3 million from the German Federal Ministry of Education and Research for the so-called CancerMark project.

16 Feb 2016

Pharmaceuticals News and Research

Regulus reports net loss of $7.2 million for fourth quarter 2015

Patient enrollment completed in vepoloxamer Phase 3 study for treatment of sickle cell disease

Dr. Elliot J. Androphy receives IGNITE grant to develop drug candidate for spinal muscular atrophy

Antibody can give more precise information about Alzheimer's disease than regular radioactive tracers

Researchers identify new group of powerful Ebola-fighting antibodies

New visiongain report on Zika virus

Novartis receives FDA Breakthrough Therapy designation for PKC412 (midostaurin)

Duke engineers develop technique to make artificial arteries that produce biochemical signals

New approach could open door to more personalized medications for diabetes patients

Parvus' novel therapeutic approach employing nanomedicines published in Nature

African Americans and Hispanics at higher risk of developing heart failure

BiondVax gains additional support from NATI for ongoing development of Universal Flu Vaccine

New treatment protects mice from MERS infection

Corvidia Therapeutics secures $26 million in Series A financing

Enzyme screening kits and samples global distribution agreement signed between Strem and Novozymes

AMRI's net revenues increase $126.4M to 46% in fourth quarter 2015

Green tea compound has high potential as treatment for rheumatoid arthritis

WRAIR begins Phase 1 clinical trial to evaluate MERS vaccine candidate

Aytu BioScience announces business strategy update and Q2 financial results

Apogenix awarded €3 million grant to develop immuno-oncology candidate APG101 as personalized therapy

Event guide: World ADC San Diego eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring